Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.

@article{Aggarwal2014ResponseTS,
  title={Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.},
  author={Rahul Aggarwal and Anna R. Harris and Carl G Formaker and Eric Jay Small and Arturo Molina and Thomas W. Griffin and Charles J. Ryan},
  journal={Clinical genitourinary cancer},
  year={2014},
  volume={12 5},
  pages={e167-72}
}
INTRODUCTION/BACKGROUND Docetaxel or AA are therapeutic options for mCRPC. We retrospectively analyzed clinical outcomes with subsequent docetaxel in patients with mCRPC after disease progression (DP) with AA to evaluate cross resistance between these therapies. PATIENTS AND METHODS Patients with chemotherapy-naive mCRPC who were treated with AA in previously reported phase I to III trials, who had DP, and were subsequently treated (not on study) with docetaxel, were included. Acquired AA… CONTINUE READING
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…